These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15100647)

  • 61. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
    Kuroda T; Rabkin SD; Martuza RL
    Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
    Blank SV; Rubin SC; Coukos G; Amin KM; Albelda SM; Molnar-Kimber KL
    Hum Gene Ther; 2002 Mar; 13(5):627-39. PubMed ID: 11916486
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.
    Berto E; Bozac A; Volpi I; Lanzoni I; Vasquez F; Melara N; Manservigi R; Marconi P
    Cancer Gene Ther; 2007 Sep; 14(9):791-801. PubMed ID: 17557110
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus.
    Adusumilli PS; Eisenberg DP; Stiles BM; Chung S; Chan MK; Rusch VW; Fong Y
    J Thorac Cardiovasc Surg; 2006 Nov; 132(5):1179-88. PubMed ID: 17059941
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
    Li H; Zeng Z; Fu X; Zhang X
    Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
    Mace AT; Ganly I; Soutar DS; Brown SM
    Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy.
    Yu Z; Li S; Huang YY; Lin SF; Fong Y; Wong RJ
    Clin Cancer Res; 2008 Mar; 14(6):1897-904. PubMed ID: 18347193
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function.
    Kelly K; Brader P; Rein A; Shah JP; Wong RJ; Fong Y; Gil Z
    FASEB J; 2008 Jun; 22(6):1839-48. PubMed ID: 18234972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rethinking herpes simplex virus: the way to oncolytic agents.
    Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
    Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma.
    Kucharczuk JC; Randazzo B; Chang MY; Amin KM; Elshami AA; Sterman DH; Rizk NP; Molnar-Kimber KL; Brown SM; MacLean AR; Litzky LA; Fraser NW; Albelda SM; Kaiser LR
    Cancer Res; 1997 Feb; 57(3):466-71. PubMed ID: 9012475
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
    Todo T; Rabkin SD; Sundaresan P; Wu A; Meehan KR; Herscowitz HB; Martuza RL
    Hum Gene Ther; 1999 Nov; 10(17):2741-55. PubMed ID: 10584921
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.
    Nawa A; Nozawa N; Goshima F; Nagasaka T; Kikkawa F; Niwa Y; Nakanishi T; Kuzuya K; Nishiyama Y
    Gynecol Oncol; 2003 Oct; 91(1):81-8. PubMed ID: 14529666
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant.
    Randazzo BP; Kesari S; Gesser RM; Alsop D; Ford JC; Brown SM; Maclean A; Fraser NW
    Virology; 1995 Aug; 211(1):94-101. PubMed ID: 7645240
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer.
    Okunaga S; Takasu A; Meshii N; Imai T; Hamada M; Iwai S; Yura Y
    Cancer Gene Ther; 2015 Apr; 22(3):163-8. PubMed ID: 25656776
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
    Wong RJ; Kim SH; Joe JK; Shah JP; Johnson PA; Fong Y
    J Am Coll Surg; 2001 Jul; 193(1):12-21. PubMed ID: 11442249
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
    Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
    J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Protective DNA vaccination by particle bombardment using BAC DNA containing a replication-competent, packaging-defective genome of herpes simplex virus type I.
    Suter M; Hefti HP
    Methods Mol Biol; 2004; 256():303-8. PubMed ID: 15024174
    [No Abstract]   [Full Text] [Related]  

  • 79. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.
    Bennett JJ; Malhotra S; Wong RJ; Delman K; Zager J; St-Louis M; Johnson P; Fong Y
    Ann Surg; 2001 Jun; 233(6):819-26. PubMed ID: 11371740
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.
    Parker JN; Meleth S; Hughes KB; Gillespie GY; Whitley RJ; Markert JM
    Cancer Gene Ther; 2005 Apr; 12(4):359-68. PubMed ID: 15678154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.